Genome Biologics

Genome Biologics, founded in 2017 and based in Munich, is a specialized CRO utilizing a sophisticated human cardiac organoid platform called TrueCardium®. Its core business is providing predictive screening services for cardiotoxicity and therapeutic efficacy, aiming to bridge the gap between conventional preclinical models and human clinical outcomes. The company's data has been reviewed by regulatory agencies like the FDA and BfArM, positioning it as a partner for de-risking cardiovascular drug development. It operates primarily as a service provider within the AI/ML and New Approach Methodologies (NAM) sectors.

TrueCardium®: A multicellular, vascularized, innervated, and functionally mature human cardiac organoid platform derived from iPSCs. It integrates cardiomyocytes, endothelial cells, fibroblasts, neurons, and immune components to model complex cardiac biology for predictive drug screening and disease modeling.

Genome Biologics competes in the niche of complex in vitro models (CIVMs) for cardiotoxicity and efficacy testing. Direct competitors include other specialist CROs offering stem cell-derived cardiac models (e.g., Ncardia, StemBioSys) and larger CROs developing organoid capabilities. It differentiates through the multicellular complexity and integrated multi-omics/AI analytics of its TrueCardium® platform.